Advanced Therapy Medicinal Products (ATMPs), also known as cell and gene therapies, are becoming increasingly common. However, they’re far more complex than “traditional” biotech products, with sophisticated requirements throughout their supply chains.
On October 20, 2022, AIM conducted a webinar on how companies can orchestrate successful supply chains for ATMPs. This paper provides a written summary of the webinar discussion.
For a time, webinar registrants can also access a recorded copy of the webinar here.